Valspar Reaffirmed at Neutral - Analyst Blog
21 February 2013 - 2:40AM
Zacks
We have retained our Neutral recommendation on paint and
coatings maker Valspar Corporation (VAL) following
our assessment of its first-quarter fiscal 2013 results. We remain
cautious given the uncertain demand environment.
Why
Maintained?
Both revenues and earnings for
the first quarter missed the Zacks Consensus Estimates, hurt by
weak market conditions. The company cut its earnings forecast for
fiscal 2013 citing a soft demand environment across some overseas
markets.
Valspar continues to see strength
in its coatings business as evidenced by new business wins. It has
a strong pipeline of new products and significant opportunities for
share gains in both its Paint and Coatings segments. The company
should also benefit from its restructuring actions in fiscal
2013.
Valspar is managing its cost well
and maintaining a cost structure that is appropriate for the
current external environment. Winning new businesses also remain a
company-wide focus that will position Valspar well for the future
and help offset lower demand in core markets. Its fastest growing
markets are the emerging economies. Valspar also remains committed
to boost shareholder return leveraging healthy cash flows.
However, Valspar’s paint segment
had a weak first quarter, partly due to depressed demand in
overseas markets. The segment’s growth has been hurt by a weak
residential housing market in Australia, which may continue to
affect sales moving ahead. The overall demand environment is
expected to be uneven in fiscal 2013.
We also remain concerned about
cost pressures associated with raw material inflation. Raw material
costs have been volatile and Valspar has experienced disruptions in
supplies of certain raw materials at various times, impacting its
ability to manufacture products.
Valspar currently carries a
short-term (1 to 3 months) Zacks Rank #3 (Hold).
Other Stocks to
Consider
Other companies in the specialty chemicals industry with
favorable Zacks Rank are Novozymes A/S (NVZMY),
Penford Corporation (PENX) and Chemtura
Corporation (CHMT). While both Novozymes and Penford
hold a Zacks Rank #1 (Strong Buy), Chemtura carries a Zacks Rank #2
(Buy).
CHEMTURA CORP (CHMT): Free Stock Analysis Report
NOVOZYMES A/S (NVZMY): Get Free Report
PENFORD CORP (PENX): Free Stock Analysis Report
VALSPAR CORP (VAL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Novenesis AS (PK) (USOTC:NVZMY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novenesis AS (PK) (USOTC:NVZMY)
Historical Stock Chart
From Nov 2023 to Nov 2024